Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations throughout Singapore, Australia, and other international regions. The company's core innovation involves employing 3D printing with bioresorbable materials to create custom, micro-structured scaffolds specifically designed to foster bone regeneration. Its product portfolio includes Osteoplug, a resorbable implant for sealing trephination burr holes during neurosurgery, and Osteomesh, another resorbable implant used in craniofacial surgery to mend various fractures, including orbital floor injuries, and to fill surgical voids. Additionally, Osteopore has forged a collaborative partnership with Livingstone Health Holding Limited to jointly pioneer new products and applications for bone and tissue regeneration.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.